We conducted this systematic review and meta-analysis to summarize the prevalence of celiac disease (CeD) among high-risk populations in China.

The global prevalence of inflammatory bowel disease (IBD) has been increasing in recent years, paralleling a growing recognition of gut dysbiosis as a pivotal etiological factor. Emerging evidence reveals intricate crosstalk between the oral and gut microbial ecosystems, with oral-derived microbiota potentially translocating to the intestinal tract through hematogenous or enteral routes. This microbial crosstalk has crystallized into an "oral-gut axis" pattern, providing novel mechanistic insights into the pathogenesis of IBD. In this review, we summarize currently available studies on the oral-gut axis and the relationship between the oral-gut axis and IBD to evaluate the role of the axis in the pathogenesis of IBD development.

Digestive system cancer (DSC) continues to pose a significant global health challenge, and cost-effective biomarkers for its early detection remain scarce. We aimed to evaluate the potential of two biological aging indicators, namely the Klemera-Doubal method age (KDMAge) and the phenotypic age (PhenoAge), for predicting DSC risk.

Ulcerative colitis (UC) is a multifactorial inflammatory bowel disease influenced by genetic susceptibility, environmental triggers, impaired intestinal epithelial barrier function, dysbiosis of gut microbiota, and immune dysregulation. Ubiquitination, a crucial post-translational modification, plays a significant role in the initiation and progression of UC. Gaining a deeper understanding of the molecular mechanisms underlying ubiquitination may help establish novel therapeutic strategies for UC. This review emphasizes the role of ubiquitination in regulating the intestinal epithelial barrier, nuclear factor (NF)-κB signaling, and immune responses, with the aim of providing new perspectives and potential directions for targeted therapies in UC.

Factors such as Helicobacter pylori eradication and the implementation of widespread early cancer screening have significantly influenced clinicopathological features and patient outcomes in gastric cancer (GC) in China. We aimed to evaluate the characteristics of GC and their evolving trends over 16 years (2007-2022) at a single center in China.

To identify the risk factors for the survival of colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM), compare the predictive performance of models based on different algorithms, and develop a risk score system to predict the survival risk of the target population.

Dyslipidemia is common in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and, along with other metabolic comorbidities, accounts for an increased cardiovascular risk. Effective treatment of dyslipidemia not only reduces such risk but may have a beneficial effect on MASLD as well. Here we reviewed published data on the efficacy and safety of available hypolipidemic treatments for MASLD. Statins are the mainstay of hypolipidemic therapy for MASLD. In patients with compensated cirrhosis, statins are safe and can improve the risks of decompensation and hepatocellular carcinoma as well as mortality. However, in those with decompensated cirrhosis, statins should not be used unless there are strong indications that outweigh the risk of adverse events. Studies on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors acting as the second-line therapy in MASLD remain scarce. Preliminary clinical data support their protective roles in MASLD; however, preclinical data raise concerns regarding safety, in particular with complete PCSK9 inhibition due to hepatocyte lipid accumulation. While more evidence is required to elucidate the role of PCSK9 inhibitors, statins should be used for the treatment of hyperlipidemia in patients with MASLD according to their cardiovascular risk stratification.

Upadacitinib (UPA) and vedolizumab (VDZ) have been approved to treat moderate-to-severe ulcerative colitis (UC); however, direct comparative data between these two regimens are lacking. We aimed to compare the effectiveness and safety of UPA and VDZ among patients with moderate-to-severe UC who had previously been treated with advanced therapies.

The association between reflux events and esophageal motility abnormality is unclear. We aimed to determine the relevance between reflux events and esophageal motility in proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD).

Patient prognosis for hepatocellular carcinoma (HCC) varies significantly even when they share the same clinical stage. We aimed to characterize the stage-specific transcriptomic landscape in super survivors with HCC and develop a prognostic gene signature for the prediction of patient survival.

Immunotherapy yields limited results in patients with colorectal cancer (CRC), emphasizing the need for a deeper understanding of the immune landscape within the tumor microenvironment. Although the C-X-C motif chemokine ligand 13 (CXCL13) recruits B cells and promotes tertiary lymphoid structure (TLS) formation, its immune function and prognostic value in CRC remain unclear. This study investigated the impact of CXCL13 on patient outcomes and CRC immune landscape.

To evaluate the efficacy and safety of tegoprazan (TPZ) compared to conventional proton pump inhibitors (PPIs) for Helicobacter pylori eradication as first- and second-line therapies.

This case report highlights a rare presentation of IgG4-related autoimmune pancreatitis with honeycomb-like cystic lesions in the pancreatic parenchyma. It discusses differential diagnoses such as VHL syndrome, emphasizing the need for clinical evaluation and corticosteroid responsiveness, which may offer insights for clinicians when managing such cases.

To investigate the rate of Crohn's disease (CD)-related bowel surgery within an inception cohort in Eastern China in the era of evolving diagnostic and therapeutic expertise.

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal (GI) tract and has been regarded as one of the most successful models of targeted therapy in solid tumors to date. In recent years, a deeper understanding of GIST biology, coupled with innovations in molecular pathology, imaging studies, endoscopic and minimally invasive techniques, as well as the development of targeted medications, has led to the evolution of the treatment paradigm into a multidisciplinary approach centered around surgery, which involves pathology, gastroenterology (including endoscopy), oncology, radiology, and interventional radiology, etc. Among all these modalities, surgical resection remains the primary and most effective treatment modality. Surgeons are expected to play a leading role in the comprehensive management of patients with GISTs. Recently, the Expert Working Group on Diagnosis and Treatment of Gastrointestinal Stromal Tumors under the Chinese College of Surgeons, Chinese Medical Doctor Association has released the Chinese Expert Consensus on Standardized Surgical Management of Gastrointestinal Stromal Tumors (2025 Edition), integrating the latest evidence and clinical insights to provide authoritative guidance for the surgical treatment of GISTs in clinical practice.

Covert hepatic encephalopathy (CHE) is one of the important entities of hepatic encephalopathy (HE). In contrast to those with overt hepatic encephalopathy (OHE), patients with CHE have no readily identifiable clinical symptoms and signs, such as disorientation and asterixis, but present with neurocognitive abnormalities detected by neuropsychological and/or neurophysiological tests. Some patients may experience mild cognitive impairment, euphoria, or anxiety, and decreased attention and calculation abilities. CHE is not only prone to OHE development, but also has harmful impacts on fitness to drive and fine operation ability, impairs health-related quality of life, and increases the risk of accidental injury, thereby resulting in worse financial status and a heavy burden to both the family and society as well as reducing the survival of cirrhotic patients. To further improve the understanding of CHE and standardize its clinical diagnosis and management, the Chinese Society of Gastroenterology, Chinese Medical Association organized experts to establish a consensus based on the updated relevant guidelines, expert consensus, research advance in the diagnosis and management of the disease, and clinical practice in China. This consensus contains 19 statements on the definition, epidemiology, etiology, precipitating factors, pathogenesis, clinical manifestations, diagnosis, treatment, prognosis, and chronic disease management of CHE. This consensus may provide the best available evidence to guide clinical practice in the diagnosis and management of patients with CHE.

Linaclotide, a guanylyl cyclase-C agonist, may enhance efficacy and tolerability when combined with polyethylene glycol (PEG) for bowel preparation. This meta-analysis evaluated linaclotide plus PEG versus PEG alone for bowel preparation prior to colonoscopy.

In this retrospective study we aimed to assess the diagnostic, monitoring, and prognostic utility of transabdominal ultrasound (TBUS) in patients with Crohn's disease in China and evaluate the utility of 16-week bowel wall thickness (BWT) reduction as a predictor of long-term outcomes.